Coastal Infusion Administers Hemlibra®

Hemlibra (emicizumab) is a medicine used to prevent or reduce bleeding in patients with hemophilia A. Hemlibra is used for patients who have developed factor VIII inhibitors; and for patients without factor VIII inhibitors if their hemophilia A is severe or moderate (with severe bleeding phenotype).

Patients with hemophilia A lack factor VIII, a substance in the body that helps the blood to clot. The active substance in Hemlibra, emicizumab, is a monoclonal antibody which has been designed to do the work that factor VIII normally does—bringing together 2 clotting factors (IXa and X) as part of a chain of reactions needed for blood to clot. Because emicizumab has a different structure to factor VIII, it is not affected by factor VIII inhibitors.

Hemlibra patients experienced significantly fewer bleeds requiring treatment, with an equivalent rate of three per year compared to 23 per year.

What It Treats

Eleprase is used to treat Hemophilia A.

Prescribed By

Hemlibra is most often prescribed by Hemotologists.

How it’s Administered

Hemlibra is administered by subcutaneous injection. Hemlibra injections take only a few minutes.

Frequency

Hemlibra is generally administered weekly for the first four weeks, then every week, two weeks, or four weeks.

Additional Resources

• Hemlibra Website
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies